Although single-agent KRAS G12C inhibitors have demonstrated clinical activity in other tumor types [26] and are increasingly considered off-label in selected patients with KRAS p.G12C-mutant BTC their efficacy as monotherapy remains limited. The gene discussed is KRAS; the disease is neoplasm.